Table 6. Incidence of VL relapse by treatment regimens.
| Treatment regimen | No. of participants |
VLR cases | Total survival time (in days) | Mean (95%CI) survival time (in days) | Incidence rate in 100-person-years for 4 years (95% CI) |
Incidence proportion for 4 years % (95% CI) |
|---|---|---|---|---|---|---|
| SSG | 168 | 3 | 244 162 | 1453.4 (1444.4, 1462.3) | 1.8 (0.6, 5.6)a | 1.8 (0.6, 5.5)a |
| MDAMB | 113 | 3 | 161 885 | 1432.6 (1401.4, 1463.8) | 2.7 (0.9, 8.4)b | 2.7 (0.8, 8.0)b |
| AMB+PMIM | 112 | 4 | 158 929 | 1419.0 (1381.2, 1456.8) | 3.7 (1.4, 9.8)c | 3.6 (1.3, 9.3)c |
| PMIM+MF | 105 | 5 | 146 218 | 1392.6 (1347.2, 1437.9) | 5.0 (2.1, 12.0)d | 4.8 (2.0, 11.1)d |
| AMB+MF | 105 | 7 | 145 819 | 1388.8 (1338.2, 1439.4) | 7.0 (3.3, 14.7)a,e | 6.7 (3.2, 13.5)a,e |
| SDAMB | 126 | 10 | 173 535 | 1377.3 (1326.5, 1428.1) | 8.4 (4.5, 15.6)a | 7.9 (4.3, 14.2)a |
| PMIM | 105 | 15 | 137 225 | 1306.9 (1232.6, 1381.2) | 16.0 (9.6, 26.5)a,b,c,d | 14.3 (8.7, 22.5)a,b,c,d |
| MF | 150 | 22 | 197 201 | 1314.7 (1255.2, 1374.1) | 16.3 (10.7, 24.7)a,b,c,d,e | 14.7 (9.8, 21.4)a,b,c,d,e |
| Total | 984 | 69 | 1 364 974 | 1387.2 (1370.5, 1403.8) | 7.6 (4.1, 14.7) | 7.0 (5.6, 8.8) |
AMB = AmBisome. MDAMB = multidose liposomal amphotericin B (AmBisome). MF = miltefosine. No. = number. PKDL = post-kala-azar dermal leishmaniasis. PMIM = paromomycin intramascular injection. SDAMB = single-dose liposomal amphotericin B (AmBisome). SSG = sodium stibogluconate. VL = visceral leishmaniasis. VLR = visceral leishmaniasis relapse.
a indicates SSG versus others with p<0.05.
b indicates MDAMB versus others with p<0.05.
c indicates AMB+PMIM versus others with p<0.05.
d indicates PMIM+MF versus others with p<0.05.
e indicates AMB+MF versus others with p<0.05.